clinprost and Peripheral-Vascular-Diseases

clinprost has been researched along with Peripheral-Vascular-Diseases* in 2 studies

Trials

1 trial(s) available for clinprost and Peripheral-Vascular-Diseases

Article	Year
A double-blind, multi-center, dose comparison study of TTC-909 for the treatment of peripheral vascular disorders. Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23 Topics: Dose-Response Relationship, Drug; Double-Blind Method; Epoprostenol; Follow-Up Studies; Humans; Pain; Peripheral Vascular Diseases; Ulcer	1995

Other Studies

1 other study(ies) available for clinprost and Peripheral-Vascular-Diseases

Article	Year
Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. Arzneimittel-Forschung, 1995, Volume: 45, Issue:9 The effect of TTC-909 (isocarbacyclin methyl ester (CAS 88931-51-5, TEI-9090) incorporated into lipid microspheres) on obstruction of the peripheral artery was studied in two different animal models. The first was a peripheral occlusion model induced by intra-arterial injection of sodium laurate in rats. The second was a tail gangrene model induced by subcutaneous injection of both ergotamine and epinephrine in rats. Intravenous bolus-administered TTC-909 at 1.0 microgram/kg resulted in the inhibition of both progression of lesions induced by sodium laurate and the extension of tail gangrene by ergotamine and epinephrine. Moreover, the inhibitory effect of TTC-909 was more potent than that of PGE1 (LM) (prostaglandin E1 incorporated into lipid microspheres). These findings suggested that TTC-909 may be clinically useful for the therapy of peripheral vascular disorders such as thromboangiitis obliterans (TAO) and atherosclerosis obliterans (ASO). Topics: Alprostadil; Animals; Drug Carriers; Epinephrine; Epoprostenol; Ergotamine; Gangrene; Lauric Acids; Liposomes; Male; Peripheral Vascular Diseases; Rats; Rats, Wistar; Tail; Vasodilator Agents	1995

Article

Year

Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease.

Arzneimittel-Forschung, 1995, Volume: 45, Issue:9

The effect of TTC-909 (isocarbacyclin methyl ester (CAS 88931-51-5, TEI-9090) incorporated into lipid microspheres) on obstruction of the peripheral artery was studied in two different animal models. The first was a peripheral occlusion model induced by intra-arterial injection of sodium laurate in rats. The second was a tail gangrene model induced by subcutaneous injection of both ergotamine and epinephrine in rats. Intravenous bolus-administered TTC-909 at 1.0 microgram/kg resulted in the inhibition of both progression of lesions induced by sodium laurate and the extension of tail gangrene by ergotamine and epinephrine. Moreover, the inhibitory effect of TTC-909 was more potent than that of PGE1 (LM) (prostaglandin E1 incorporated into lipid microspheres). These findings suggested that TTC-909 may be clinically useful for the therapy of peripheral vascular disorders such as thromboangiitis obliterans (TAO) and atherosclerosis obliterans (ASO).

Topics: Alprostadil; Animals; Drug Carriers; Epinephrine; Epoprostenol; Ergotamine; Gangrene; Lauric Acids; Liposomes; Male; Peripheral Vascular Diseases; Rats; Rats, Wistar; Tail; Vasodilator Agents

1995